Report
(Sponsored) Oncodesign Precision Medicine - Promising radiotheranostic alliance
Last night, OPM announced a partnership with German ‘Navigo Proteins' for the development of radiotherapeutic drug candidates focused on two oncology targets. OPM will fund the program over the next three years. No financial details disclosed.Navigo's precision targeting technology is based on so-called Affilins®, small proteins derived from human ubiquitin, which offer several benefits over traditional antibodies in radiotheranostic development.Promising partnership for OPM which supports the company's Promethe® technology platform, which aims to develop new radioligand therapies. Due to its early stage and the lack of insight in pursued targets and clinical timelines, we do not yet factor in any
Underlying
Oncodesign Precision Medicine
Provider
Degroof Petercam
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
David Seynnaeve, PhD
Other Reports on these Companies
Other Reports from Degroof Petercam
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.